Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Protocols


EDRN investigators protocols. The following is a list of the EDRN protocols that have been captured and curated. Additional information will be added as it is available. Contact information is provided as part of the detail for each protocol.


Title Abstract Investigator
A Methylation Panel for Bladder Cancer Gazdar, Adi
A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens To determine the relative sensitivity and specificity of cytology and fluorescence in situ hybridization (FISH) for the detection of lung cancer in ... Halling, Kevin C
A prediction model for lung cancer diagnosis that integrates genomic and clinical features. Lung cancer is the leading cause of cancer death due, in part, to lack of early diagnostic tools. Bronchoscopy represents a relatively noninvasive initial ... Beane, Jennifer
A serum circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer Lung cancer is the first cause of cancer mortality worldwide, and its early detection is currently the main available strategy to improve disease prognosis. ... Bianchi, Fabrizio
Affinity-based strategies to fast track development of colon cancer biomarkers Our goal is to discover plasma and tissue-based tumor biomarkers that work well enough together to identity colon cancer at early stages, lead to accurate ... Lampe, Paul
Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Lung cancer is the leading cause of death from cancer in the US and the world. The high mortality rate (80-85% within 5 years) results, in part, from a lack of ... Spira, Avrum
An epigenetic marker panel for detection of lung cancer using cell-free serum DNA PURPOSE: We investigated the feasibility of detecting aberrant DNA methylation of some novel and known genes in the serum of lung cancer ... Begum, Shahnaz
Antibodies Against Tumor Antigens or Mucin Epitopes in Ovarian Cancer Cramer, Daniel
Assay of TMPRSS2:ERG and PCA in Canary PASS The identification of biomarkers that, at the time of diagnosis, associate with the presence of, or progression to, aggressive prostate cancer will transform ... Lin UW, Daniel W.
Assessment of Clinical Potential of Digital SNP Analysis Helzlsouer, Kathy
Aurora Kinase A as a Biomarker for the Detection of Bladder Cancer - Supplemental Pre-Validation Protocol Czerniak, Bogdan
Autoantibodies in lung cancer: possibilities for early detection and subsequent cure. BACKGROUND: People with lung cancer usually present at a late stage in the course of their disease when their chances of long-term survival are low. At ... Chapman, Caroline J.
Autoantibody Approach for Serum-Based Detection of Head and Neck Cancer Our long term goal is to improve survival of patients with head and neck squamous cell carcinoma (HNSCC) through early detection using simple noninvasive serum ... Tainsky, Michael A.
BRSCW Applicant: Buechler - Biosite Inc (2009) Over 40 marker assays are available to run on the samples. These include markers such as Osteopontin, Mesothelin, Periostin, Endoglin, intestinal Fatty Acid ... Buechler, Joe
BRSCW Applicant: Diamandis - Mt Sinai (2006) Examine kallikreins as ovarian cancer biomarkers and determine sensitivity and specificity of panel Diamandis, Eleftherios P.
BRSCW Applicant: Abbott 2014 Our earlier glycoproteomic studies have identified bisecting glycoslyation and core fucosylation changes on particular glycoproteins in endometrioid ovarian ... Abbott, Karen
BRSCW Applicant: Birrer Massachusetts General Hospital 2013 Birrer, Michael
BRSCW Applicant: Morre - NOX Technologies Inc. (2009) Evaluation using NOX Technologies ECTO-NOX blot diagnostic 2-D gel electrophoretic cancer detection system in combination with a sandwich ELISA of our ... Morre, D. James
BRSCW Applicant: Tuszynski - Temple University (2012) Feng, Ziding
BRSCW Applicant: Wilson - EIC Laboratories, Inc (2007) Samples were returned unused. Analysis never completed. Wilson, Michael S.
BRSCW Application: Lokshin - Univ of Pitts (2008) One KLK,(KLK6) ranked 6th among all tested biomarkers(approx.50) Lokshin, Anna
BRSCW Application: Mathew - Meso Scale (2006) Mathew, Anu
Barrett's Esophagus Methylation Profiles We propose a nested case-control study of biomarkers in the setting of BE. By bringing together research institutions with large populations of patients with ... Meltzer, Stephen
Basophile: Accurate Fragment Charge State Prediction Improves Peptide Identification Rates In shotgun proteomics, database search algorithms rely on fragmentation models to predict fragment ions that should be observed for a given peptide sequence. ... Wang, Dong
Benign Breast Disease Team Project This procedure applies to identification of the cohort and of cases and controls from the cohort of women with the diagnosis of benign breast conditions, and ... Engstrom, Paul
Benign Breast Disease/DCIS Team Project To identify women diagnosed with atypical ductal hyperplasia (ADH) who are at increased risk of developing invasive breast cancer (IBC) and who might benefit ... Engstrom, Paul
Biomarker Detection Using NAPPA Tumor Antigen Arrays: EDRN Supplement The overall goal of this project application for the EDRN set-aside funds is to focus our collaborative efforts to identify p53 mutation-specific antibody ... Anderson, Karen
Biomarker Dev Lab At Moffitt Supplement Tockman, Melvyn S.
Biomarker Development Laboratory Zhao, Yingming
Biomarker Discovery for Renal Cell Carcinoma Through Serum, Urine and Tissue Protein Profiles Basler, Joseph W.
2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.